BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34425470)

  • 1. PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules.
    Liang M; Gong D; Wang L; Liang X; Meng J; Huang W; Zhou J
    Cancer Treat Res Commun; 2021; 28():100437. PubMed ID: 34425470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX5 Haploinsufficiency Induces Low T Cell Infiltration in the Cancer Microenvironment via Reduced Chemokines.
    Wang L; Liang X; Liang M; Li D; Gu J; Huang W; Zhou J
    Curr Mol Med; 2022; 22(9):826-834. PubMed ID: 34872475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line.
    Gu J; Li T; Zhao L; Liang X; Fu X; Wang J; Shang Z; Huang W; Zhou J
    Biomed Res Int; 2017; 2017():5326370. PubMed ID: 28316978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX5 haploinsufficiency induce cancer cell dormancy in Raji cells.
    Liang X; Gu J; Li T; Zhao L; Fu X; Zhang W; Wang J; Shang Z; Huang W; Zhou J
    Exp Cell Res; 2018 Jun; 367(1):30-36. PubMed ID: 29453973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
    Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
    J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowat-Wilson Syndrome.
    Frith K; Munier CML; Hastings L; Mowat D; Wilson M; Seddiki N; Macintosh R; Kelleher AD; Gray P; Zaunders JJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
    Familiades J; Bousquet M; Lafage-Pochitaloff M; Béné MC; Beldjord K; De Vos J; Dastugue N; Coyaud E; Struski S; Quelen C; Prade-Houdellier N; Dobbelstein S; Cayuela JM; Soulier J; Grardel N; Preudhomme C; Cavé H; Blanchet O; Lhéritier V; Delannoy A; Chalandon Y; Ifrah N; Pigneux A; Brousset P; Macintyre EA; Huguet F; Dombret H; Broccardo C; Delabesse E
    Leukemia; 2009 Nov; 23(11):1989-98. PubMed ID: 19587702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.
    Iacobucci I; Lonetti A; Paoloni F; Papayannidis C; Ferrari A; Storlazzi CT; Vignetti M; Cilloni D; Messa F; Guadagnuolo V; Paolini S; Elia L; Messina M; Vitale A; Meloni G; Soverini S; Pane F; Baccarani M; Foà R; Martinelli G
    Haematologica; 2010 Oct; 95(10):1683-90. PubMed ID: 20534699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoallelic expression of Pax5: a paradigm for the haploinsufficiency of mammalian Pax genes?
    Nutt SL; Busslinger M
    Biol Chem; 1999 Jun; 380(6):601-11. PubMed ID: 10430025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
    Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
    Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy.
    Yan M; Himoudi N; Pule M; Sebire N; Poon E; Blair A; Williams O; Anderson J
    Cancer Res; 2008 Oct; 68(19):8058-65. PubMed ID: 18829564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
    Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
    Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic regulation of bone development.
    Horowitz MC; Lorenzo JA
    Adv Exp Med Biol; 2007; 602():47-56. PubMed ID: 17966387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of the transcription factor PAX5 in childhood acute leukemic cells].
    Zhang B; Tie LJ; Ye QD; Gu LJ; Tang JY; Yuan XL; Shen LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):6-10. PubMed ID: 16584581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
    Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
    Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.